A Phase 1/1b Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191(azercabtagene zapreleucel or“azer-cel”), in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin


NCT Number:



Study Status:






The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR0191 to treat certain types of cancers. PBCAR0191 is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR0191 came from people who have donated their blood. The donated T cells have been genetically changed, so that they may be able to kill some types of cancer cells.

Are you Eligible? (Inclusion Criteria)

  • Must be 18 years of age or older
  • Must have received at least 2 prior chemotherapy-containing regimens, consistent with standard of care treatment guidance
  • Must have previously failed at least 2 lines of chemotherapy/immunotherapy that included ibrutinib and idelalisib plus rituximab.

Specialty Area(s)

Leukemia, Acute Lymphocytic leukemia, Lymphoma, Non-Hodgkin's Lymphoma, Immunotherapy

Principal Investigator

Profile Headshot
  • Director of Translational Research, Blood and Marrow Transplantation Program
  • Director of the Cell Therapy Program

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032